OBJECTIVE: Recent research implicates the catechol-O-methyltransferase (COMT) ValMet polymorphism in stress sensitivity, through modulation of hypothalamic-pituitary-adrenal (HPA) function. In healthy samples, Met homozygosity has been associated with greater HPA activity (i.e., cortisol) and stress sensitivity, though findings are mixed among clinical samples. To date, there are no reports examining baseline or longitudinal changes in HPA activity as a function of COMT genotype in youth. This study tested the hypothesis that COMT genotype would be associated with cortisol secretion in normal and at-risk adolescents; specifically, that COMT genotype would be linked in a dose-response manner such that Met homozygotes would have the highest salivary cortisol levels, followed by heterozygotes, then Val homozygotes. In addition, this study examined the relation of COMT genotype with longitudinal changes in cortisol. METHODS: This study examined the association of COMT with salivary cortisol across a 1-year period in healthy and at-risk adolescents with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision Axis II diagnoses. RESULTS: Results indicated higher cortisol levels for Met homozygotes (compared with heterozygotes and Val homozygotes) at the 1-year follow-up, and increased mean cortisol levels across a 1-year period among Met carriers, suggesting that COMT associates with differences in cortisol secretion during adolescence. CONCLUSION: Findings are discussed with respect to COMT genotype as a potential genetic indicator of psychiatric risk that modulates developmental changes in HPA activity.
OBJECTIVE: Recent research implicates the catechol-O-methyltransferase (COMT) ValMet polymorphism in stress sensitivity, through modulation of hypothalamic-pituitary-adrenal (HPA) function. In healthy samples, Met homozygosity has been associated with greater HPA activity (i.e., cortisol) and stress sensitivity, though findings are mixed among clinical samples. To date, there are no reports examining baseline or longitudinal changes in HPA activity as a function of COMT genotype in youth. This study tested the hypothesis that COMT genotype would be associated with cortisol secretion in normal and at-risk adolescents; specifically, that COMT genotype would be linked in a dose-response manner such that Met homozygotes would have the highest salivary cortisol levels, followed by heterozygotes, then Val homozygotes. In addition, this study examined the relation of COMT genotype with longitudinal changes in cortisol. METHODS: This study examined the association of COMT with salivary cortisol across a 1-year period in healthy and at-risk adolescents with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision Axis II diagnoses. RESULTS: Results indicated higher cortisol levels for Met homozygotes (compared with heterozygotes and Val homozygotes) at the 1-year follow-up, and increased mean cortisol levels across a 1-year period among Met carriers, suggesting that COMT associates with differences in cortisol secretion during adolescence. CONCLUSION: Findings are discussed with respect to COMT genotype as a potential genetic indicator of psychiatric risk that modulates developmental changes in HPA activity.
Authors: Sonia J Lupien; Charles W Wilkinson; Sophie Brière; Catherine Ménard; N M K Ng Ying Kin; N P V Nair Journal: Psychoneuroendocrinology Date: 2002-04 Impact factor: 4.905
Authors: Jon-Kar Zubieta; Mary M Heitzeg; Yolanda R Smith; Joshua A Bueller; Ke Xu; Yanjun Xu; Robert A Koeppe; Christian S Stohler; David Goldman Journal: Science Date: 2003-02-21 Impact factor: 47.728
Authors: Ruud van Winkel; Cécile Henquet; Araceli Rosa; Sergi Papiol; Lourdes Fananás; Marc De Hert; Jozef Peuskens; Jim van Os; Inez Myin-Germeys Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2008-01-05 Impact factor: 3.568
Authors: C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker Journal: Neuroscience Date: 2013-01-05 Impact factor: 3.590
Authors: Lori D Hill; Kathryn G Ewens; Brion S Maher; Timothy P York; Richard S Legro; Andrea Dunaif; Jerome F Strauss Journal: Mol Cell Endocrinol Date: 2011-12-08 Impact factor: 4.102
Authors: Elaine F Walker; Hanan D Trotman; Sandra M Goulding; Carrie W Holtzman; Arthur T Ryan; Allison McDonald; Daniel I Shapiro; Joy L Brasfield Journal: Dev Psychopathol Date: 2013-11
Authors: Dennis Hernaus; Dina Collip; Johan Lataster; Jenny Ceccarini; Gunther Kenis; Linda Booij; Jens Pruessner; Koen Van Laere; Ruud van Winkel; Jim van Os; Inez Myin-Germeys Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: Moniek Janse; Martijn van Faassen; Ido Kema; Ans Smink; Adelita V Ranchor; Joke Fleer; Mirjam A G Sprangers Journal: PLoS One Date: 2015-08-27 Impact factor: 3.240
Authors: Kristel Klaus; Kevin Butler; Simon J Durrant; Manir Ali; Chris F Inglehearn; Timothy L Hodgson; Humberto Gutierrez; Kyla Pennington Journal: Brain Behav Date: 2017-04-12 Impact factor: 2.708
Authors: Diana O Perkins; Clark D Jeffries; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Robert Heinssen Journal: Schizophr Bull Date: 2014-08-06 Impact factor: 9.306